New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 30, 2014
09:06 EDTTKPYYTakeda unit granted orphan status for pancreatic cancer treatment
Millennium Pharmaceuticals' treatment of pancreatic cancer was granted FDA orphan designation, according to a post to the regulator's site. Reference Link
News For TKPYY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 4, 2016
08:05 EDTTKPYYSeattle Genetics to receive $20M milestone payment under ADCETRIS collaboration
Seattle Genetics (SGEN) announced that it will receive a one-time $20M milestone payment under its ADCETRIS collaboration with Takeda Pharmaceutical Company Limited (TKPYY). The milestone was triggered by Takeda surpassing annual ADCETRIS net sales of $200M in its territory during 2015. The milestone will be recognized as royalty revenue in the first quarter of 2016. In addition, the company announced that the European Commission recently approved a Type II variation that includes data on the retreatment of adult patients with relapsed or refractory Hodgkin lymphoma or R/R systemic anaplastic large cell lymphoma who previously responded to ADCETRIS and who later relapse. The label update follows a positive opinion from the Committee for Medicinal Products for Human Use in October 2015.
05:17 EDTTKPYYTakeda announces FDA PDAC supports effectiveness of Brintellix
Subscribe for More Information
February 3, 2016
07:32 EDTTKPYYTaked, Mersana Therapeutics expand partnership for XMT-1522
Mersana Therapeutics and Takeda Pharmaceutical announced that they have entered a new strategic partnership granting Takeda rights to Mersana's lead product candidate, XMT-1522, outside the United States and Canada. The deal also expands an existing collaboration between the companies to provide Takeda with additional access to Mersana's Fleximer antibody-drug conjugate platform and grants Mersana an option at the end of Phase 1 to co-develop and co-commercialize one of these programs in the United States. In addition, the companies will co-develop new payloads for use with ADCs. XMT-1522 is an investigational, Fleximer-based ADC therapy that targets HER2-expressing tumors, including breast, gastric and non-small cell lung cancers. Preclinical data suggest that XMT-1522 may have anti-tumor activity in patients with HER2 low-expressing cancers as well as in patients with HER2 high-expressing cancers that do not respond to currently available HER2-targeting therapies. Mersana anticipates filing an Investigational New Drug application for XMT-1522 with the U.S. Food and Drug Administration in mid-2016. Takeda and Mersana will co-develop XMT-1522, and Mersana will lead execution of the Phase 1 trial. Mersana will retain full commercial rights in the United States and Canada while Takeda will have rights in rest of world. Beyond development and commercialization of XMT-1522, the expanded partnership also grants Takeda access to additional targets within Mersana's Fleximer-based ADC platform, with Mersana retaining the right to select one program at the end of Phase 1 for co-development and co-commercialization in the United States. Takeda and Mersana will also work together, leveraging Takeda's proprietary small molecule libraries, to identify and develop novel payloads that both parties will be able to use in new ADC therapies. Takeda signed agreements with Mersana through its wholly owned subsidiary, Millennium Pharmaceuticals, Inc., under which, Mersana will receive an upfront payment of $40 million and an additional payment of $20 million upon clearance of the IND for XMT-1522 by the FDA. Subject to the success of the XMT-1522 and ADC programs, Mersana is eligible to receive milestone payments of more than $750 million combined, as well as royalties. Takeda will also invest up to $20 million in equity in future rounds of Mersana financing.
07:17 EDTTKPYYFDA Psychopharmacologic Drugs Advisory Committee to hold a meeting
Subscribe for More Information
January 27, 2016
12:01 EDTTKPYYTakeda says FDA approves Dexilant SoluTab
Takeda Pharmaceuticals U.S.A. announced that the FDA approved Dexilant SoluTab delayed-release orally disintegrating tablets, a new formulation of dexlansoprazole that can be taken by allowing the tablet to melt in the patient's mouth. Dexilant SoluTab is a proton pump inhibitor indicated for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease and the maintenance of healed erosive esophagitis and relief of heartburn in adults 18 years and older. Dexilant SoluTab is a PPI with dual delayed release technology that is designed to provide two separate releases of medication.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use